SEC Tracker
Get the app

Replimune Group REPL

Replimune Group reports $57.12M net loss

Form
10-Q
Filed
Importance
Major
  1. Net loss: $57.12M for fiscal Q2 2027
  2. Diluted EPS: -$0.54 for fiscal Q2 2027
  3. Cash and equivalents: $307.83M as of Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Replimune Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

1 new risk factor · 4 removed · 2 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$56.28M−$68.25M+18%
Net income−$57.12M−$69.77M+18%
Operating cash flow−$47.7M−$75.73M+37%
Cash$307.83M$185.36M+66%
New risk factors (1)
  • The potential market opportunities for TUDRIQEV or our product candidates are difficult to estimate and will depend in large part on the drugs with which TUDRIQEV or our product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market opportunity for…
Removed risk factors (4)
  • We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice…
  • We have concentrated all of our research and development efforts on our product candidates based on our proprietary RPx platform, and our future success depends on the successful development of this therapeutic approach. There can be no assurance that any development problems we experience in connection with our…
  • TUDRIQEV and our Phase 1/2 clinical trial with RP2 where we intend to use nivolumab and may potentially do so for other clinical trials in the future; Roche has agreed to provide atezolizumab and bevacizumab for use in our RP2 study of hepatocellular cancer, or HCC.
  • Our authorized share capital limits the number of shares we may issue, and if our stockholders do not approve the proposed increase in our authorized common stock, our ability to raise additional capital, complete strategic transactions and grant equity compensation could be materially constrained. +2 more paragraphs
New legal mentions (2)
  • The Company and the other defendants filed a motion to dismiss the second amended complaint on August 17, 2026 which is scheduled to be fully briefed in December 2026.
  • On September 18, 2026, Lead Plaintiff in the Jboor action filed a motion to consolidate the related action in Toor v. Replimune Group, Inc. et al., Case No. 1:26-cv-13612 into the Jboor action. +2 more paragraphs

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025